- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06430476
EMI Therapy for Depression in Hong Kong
Ecological Momentary Intervention (EMI) as Augmentative Therapy for Depression in Clinical Sample in Hong Kong
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Major Depressive Disorder (MDD) is the leading contributors to disability-adjusted life years, with a burden comparable to that of cardiovascular disease. Among the core symptoms of MDD, rumination stands out as a particularly pernicious factor. Rumination is dysfunctional disturbing thinking; a maladaptive pattern of regulating thoughts and emotions characterized by a repetitive focus on negative thoughts, such as dwelling on negative memories and analyzing events without taking actions. Rumination amplifies negative cognitions and attenuates the effect of adapting problem-solving strategy, decreasing the motivation of patients to cope with stressful encounters and become more vulnerable to momentary low mood. Interventional strategies (such as Cognitive Bias Modification) targeting rumination involves increases one's ability to become aware of their own rumination and supporting them to adapt alternative thinking habits. Complementary techniques such as mindfulness and relaxation do not involve the reframing of negative thoughts but rather promote the acceptance of these thoughts, in this way, it allows one become more aware of distractions and repetitive past or future thinking events. The ESM, a structured self-report diary technique several times a day over a number of days using mobile devices zooming in on the micro-level of experience and behavior, presents a novel and promising approach to accurately track symptoms and experience by minimizing recall bias and capturing the natural fluctuations of symptom on a more immediate, granular level. The ESM-derived intervention (ESM-I), uses personalized mobile feedback to effectively treat depressive symptoms. Importantly, increasing evidence from randomised controlled trials (RCTs) have shown ESM-I as effective means to augment interventions in depression. While improving rumination is key the core depression symptom, ESM-I has yet to specifically target rumination, and the mechanisms by which ESM-I exert therapeutic effects warrant further investigation.
Objectives:
Our study aims to investigate the efficacy of a newly developed smartphone based 2-week Ecological Momentary Intervention (EMI) in comparison with an active control group receiving only ESM, as an innovative, online-based, accessible, and augmentative treatment for depression. This intervention is designed to be both timely and adaptive, targeting the core symptom of anhedonia in a clinical sample within Hong Kong.
Design:
This is a single-center, randomized, double-blind, sham-controlled trial with three assessment time points: Baseline (T0), post-intervention (T1) and 1-month post-intervention (T2).
Ecological Momentary Assessment (EMA): After providing informed consent, participants will install the "m-path" smartphone-based application, which is an open-source ESM program developed by KU Leuven. Following a briefing and practise run, participants will be randomly prompted within designated 3-hour blocks three times daily to complete a 5-minute questionnaire assessing their momentary affect, rumination levels, and suicidality, using visual analogue scales ranging from 0 (lowest) to 100 (highest). There will be 14 EMA questions covering affect (8 questions), suicidality (2 questions), and rumination (4 questions).
Ecological Momentary Intervention (EMI): Embedded within the last EMA survey, the EMI arm will include interactive tasks when a participant's computed rumination score (i.e., mean score of the four EMA rumination questions) reaches above the 80th percentile of their own cumulative score, or if the raw rumination score reach above 70 out of 100. The intervention comprises of short exercises (most can be completed within 1-3 minutes) rooted in cognitive bias modification (CBM) techniques. Participants will interact with instructions and multimedia formats based on CBM module framework based on reflection / brooding. Participants will continue treatment with their psychiatrists who will be blinded to group allocation.
Variables:
- Hamilton Depression Rating Scale (HDRS)
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- Social and Occupational Functioning Assessment scale (SOFAS)
- Role Functioning Scale (RFS)
- Global Functioning: Social Scale and Role Scale
- Short Form Health Survey (SF-12)
- General Self Efficacy Scale
- Rumination Response Scale (RRS)
- System Usability Scale - Chinese version
- Beck Scale for Suicidal Ideation
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- University of Hong Kong
-
Contact:
- Ka Ying Heidi Lo
- Phone Number: 2255 4486
- Email: lokaying@hku.hk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 16-65 years
- Cantonese-speaking ethnic Chinese
- Diagnosis of major depressive episode (MDE) established by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorder 5th Edition (DSM-V)
- 17-item Hamilton Depression Rating Scale (HDRS) ≥ 14 at screening and at baseline (i.e. moderate to severe depression)
- Having a smartphone with Internet access and iOS or Android operating system.
Exclusion Criteria:
- Patients who could not read Chinese, are unable to provide informed consents
- Comorbid with other Axis I diagnoses (especially schizoaffective disorder)
- With an unstable medical condition or current substance abuse
- Have a score of ≥4 on any one of the three items on Positive and Negative Syndrome Scale (P1 Delusion, P2 Conceptual disorganization, P3 Hallucination)
- Marked risk of self-harm or suicide that could not be safely managed in an outpatient clinic setting
- Currently receiving any other weekly psychosocial therapy
- Unable to use a smartphone-based application due to cognitive impairment or learning disability or inadequate vision.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: EMA
Ecological momentary assessment (EMA) arm: participants will receive three ecological momentary assessment (EMA) prompts daily within three time blocks spread out throughout the day.
Within each prompt, participants will answer 14 questions regarding affect, suicidality, and rumination.
Afterwards, they will be shown a video clip extracted from a popular and longstanding soap opera in Chinese that lasts between three to four minutes.
Each prompt would take around 8 minutes to complete.
In total, participants will complete 70 EMA prompts during the intervention period.
|
A phone-based exercise containing relaxation videos carried out on an experience sampling platform m-Path
|
|
Experimental: EMI
EMI arm: participants in this arm will receive two ecological momentary assessment (EMA) prompts and one econological momentary intervention (EMI) prompt daily.
The EMA prompts would be identical to the ones in the EMA arm without the video clip at the end.
The EMI prompt would contain an interactive task designed to counter ruminative thoughts.
Examples of the interactive tasks include: mindfulness exercises (mindful walking), cognitive reappriasal, strengths recognition, etc.
Each EMI prompt would last around 3-5 minutes.
|
A phone-based intervention containing exercises meant to reduce ruminative thoughts carried out on an experience sampling platform m-Path
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Montgomery-Åsberg Depression Rating Scale (MADRS)
Time Frame: T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measuring change in depressive symptoms; score ranges from 0 (minimum) to 60 (maximum); higher score indicates more severe depressive symptoms.
|
T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
Ecological Momentary Assessment (EMA) outcomes
Time Frame: During intervention
|
Average score among the following aspects: positive and negative affect (four questions each), active and passive suicidality (one question each), rumination (four questions); score ranges from 0 (minimal) to 100 (maximum), with a higher score indicating a greater value of measured aspect.
|
During intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Role Functioning Scale (RFS)
Time Frame: T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measures role functioning in four areas: work productivity, independent living, immediate and extended social network relationships; score ranges from 0 (minimum) to 7 (maximum) on each aspect, higher score indicates better role functioning
|
T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
Global Functioning: Social Scale and Role Scale
Time Frame: T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measures social and role functioning; score ranges from 1 (minimum) to 10 (maximum); higher score indicates better social/role functioning
|
T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
General Self Efficacy Scale
Time Frame: T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measures self-reported self-efficacy; score ranges from 10 (minimum) to 40 (maximum), with higher scores indicating more self-efficacy
|
T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
Rumination Response Scale (RRS)
Time Frame: T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measures self-reported rumination responses; score ranges from 10 (minimum) to 40 (maximum), with higher scores indicating higher levels of ruminative responses styles.
|
T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
Beck Scale for Suicidal Ideation
Time Frame: T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measures self-reported suicidal ideation; score ranges from 0 (minimum) to 38 (maximum), with higher scores indicating a greater risk of suicide.
|
T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
Clinical Global Impression Scale
Time Frame: T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measures the severity of illness and global improvement following an intervention; scores ranges from 1 (normal/very much improved) to 7 (most severely ill/very much worse), with higher scores indicating worse outcome.
|
T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
Social and Occupational Functioning Assessment scale (SOFAS)
Time Frame: T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measures social and occupational functioning across work functioning, independent functioning, immediate and extended social network functioning; score ranges from 0 (minimum) to 100 (maximum), higher score indicates higher social and occupational functioning ability.
|
T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
System Usability Scale - Chinese version
Time Frame: T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
to assess acceptability and feedback regarding conducting EMA and EMI on mPath platform; scores ranges from 10 (minimum) to 50 (maximum), with higher scores indicating higher perceived usability of the systems involved.
|
T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
Hamilton Depression Rating Scale (HDRS) - 17 items
Time Frame: T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measuring depressive symptoms, score ranges from 0 (minimum) to 53 (maximum); higher score indicates more severe depressive symptoms.
|
T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
|
WHO-5 Well-being Index
Time Frame: T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Measures wellbeing at a primary care setting; score ranges from 0 (minimum) to 100 (maximum) and is calculated by summing the total score and multiply it by 4. Higher score indicates better wellbeing
|
T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86. doi: 10.1016/s0005-7916(00)00012-4.
- Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000 Apr;101(4):323-9.
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596
- Wang, Y., Lei, T., & Liu, X. (2020). Chinese System Usability Scale: Translation, Revision, Psychological Measurement. International Journal of Human-Computer Interaction, 36(10), 953-963. https://doi.org/10.1080/10447318.2019.1700644
- Mestdagh M, Verdonck S, Piot M, Niemeijer K, Kilani G, Tuerlinckx F, Kuppens P, Dejonckheere E. m-Path: an easy-to-use and highly tailorable platform for ecological momentary assessment and intervention in behavioral research and clinical practice. Front Digit Health. 2023 Oct 18;5:1182175. doi: 10.3389/fdgth.2023.1182175. eCollection 2023.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMI_depression
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild to Moderate Depression
-
Osmaniye Korkut Ata UniversityCompletedDepressive Symptoms Mild to Moderate in SeverityTurkey (Türkiye)
-
Norwegian Institute of Public HealthGöteborg University; University of Bergen; University of Tromso; Sussex Partnership... and other collaboratorsActive, not recruitingAnxiety | Mild to Moderate DepressionNorway
-
Norwegian Institute of Public HealthGöteborg University; University of Bergen; The Research Council of Norway; Sussex...Completed
-
National University of SingaporeRecruiting
-
Annecto LLCHoly Redeemer HospitalTerminatedMild to Moderate DepressionUnited States
-
Fujian Shengdi Pharmaceutical Co., Ltd.RecruitingMild to Moderate HypertensionChina
-
The University of Hong KongGuang'anmen Hospital of China Academy of Chinese Medical Sciences; The First... and other collaboratorsCompletedMild-to-moderate DepressionChina
-
PiLeJeCompletedMild to Moderate DepressionFrance
-
Bar-Ilan University, IsraelUniversity of California, Berkeley; United States - Israel Binational Science...RecruitingDepression and/or Anxiety in the Mild-to-moderate RangeUnited States, Israel
-
Fundació Sant Joan de DéuUnknown
Clinical Trials on EMA
-
Click Therapeutics, Inc.CompletedCovid19 | Stress | Stress, Psychological | LonelinessUnited States
-
Northeastern UniversityNational Center for Advancing Translational Sciences (NCATS)Completed
-
Massachusetts General HospitalBoston UniversityRecruitingSchizophrenia | PsychosisUnited States
-
University Hospital, MontpellierCentre Hospitalier Universitaire de Nīmes; Instituto de Investigación Sanitaria... and other collaboratorsRecruitingSuicidal Ideation | Suicidal Behaviour | Personal History of a Recent Suicidal CrisisFrance, Spain
-
The University of Hong KongActive, not recruiting
-
Johns Hopkins UniversityNational Institute on Aging (NIA)Completed
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingSuicidal Ideation | Self HarmUnited States
-
Chestnut Health SystemsNational Institute on Drug Abuse (NIDA)CompletedRecovery | Substance Use Disorder (SUD)United States
-
Hôpital le VinatierInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
-
University of OklahomaWithdrawnCervical Cancer | Head and Neck Cancer | Gynecologic Cancer | Endometrial CancerUnited States